SY-7021 / Shouyao Holdings - LARVOL DELTA

SY-7021, a novel DNA-PK inhibitor, exhibits significant anti-tumor activity in vitro and in vivo (AACR 2024) - "Cancer therapies such as ionizing radiation or topoisomerase II inhibitors (for example, doxorubicin) induce DNA double-strand breaks (DSBs), which can subsequently be repaired by homologous recombination or non-homologous end joining (NHEJ). In addition, SY-7021 demonstrates good PK properties and acceptable safety profiles in in vivo studies. Collectively, SY-7021, a potent and selective DNA-PK inhibitor, shows significant inhibition on tumor growth in in vitro and in vivo studies, providing a rationale treatment for multiple tumors in monotherapy or in combination with other agents."

Preclinical • Oncology • CHEK2